CRISPR-based genome editing in primary human pancreatic islet cells

CRISPR-based genome editing in primary human pancreatic islet cells

The editing of primary human islets could provide insight into diabetes pathogenesis. Here the authors use CRISPR-Cas9 to target regulatory elements associated with T2D susceptibility.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Romina J. Bevacqua, Xiaoqing Dai, Jonathan Y. Lam, Xueying Gu, Mollie S. H. Friedlander, Krissie Tellez, Irene Miguel-Escalada, Silvia Bonàs-Guarch, Goutham Atla, Weichen Zhao, Seung Hyun Kim, Antonia A. Dominguez, Lei S. Qi, Jorge Ferrer, Patrick E. MacDonald, Seung K. Kim
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/22d2b0339efc4aa29c30bb51db113c85
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/22d2b0339efc4aa29c30bb51db113c85

Documents similaires